( onceptclinical trials as a novel compo...)Independent publication supports the profile of CeNeS phase II,compound, CNS 5161,Health

oncept clinical trials as a novel compound for the treatment of neuropathic pain. Two Phase I studies using CNS 5161 administered intravenously have been completed in male volunteers. The first study demonstrated the safety and tolerability of selected doses of CNS 5161 and the second that at a dose of CNS 5161 that was well tolerated, analgesic effects were evident in an experimental model of pain. Two phase IIa studies have been completed giving single dose intravenous infusions of CNS 5161 to patients with long standing intractable neuropathic pain. A total of 48 patients have received CNS 5161; 10 patients in an initial study and 38 patients in a study completed in 2005. Both studies reported analgesic effects of CNS 5161 at doses that were well tolerated by the patients.

'"/>




Page: 1 2 3
Related medicine technology :

1. Molecular Target of Bradmers Neuradiab Further Validated by Independent Findings
2. Independent Publication Confirms Growing Therapeutic Challenge of T315I Mutation in Patients with CML, Notes ChemGenex
3. Independent Publication Confirms Growing Therapeutic Challenge of T315I Mutation in Patients with CML, Notes ChemGenex
4. Study Continues to Show Patients With Myelodysplastic Syndromes Treated With Revlimid are Living Longer and Remaining Transfusion Independent
5. Data Presented at AACR Meeting Shows Bavituximab Equivalent Plus Docetaxel Reduces Growth of Both Hormone-Dependent and Hormone-Independent Prostate Cancer by Up to 94 Percent in Preclinical Studies
6. Major New Review Supports the Broader Potential of CeNeS COMT Inhibitor Discovery Programme
7. CeNeS Pharmaceuticals Plc Announces Preliminary Results for The Year Ending 31 December 2006
8. CeNeS Pharmaceuticals plc: Update on Successful Phase III results announced on Lead Product M6G
9. Liraglutide provides significantly better glucose control than insulin glargine in phase 3 study
10. Positive results from placebo-controlled phase IIa study in patients suffering from house dust mite allergy
11. Isotechnikas independent data monitoring committee conducts review of phase 2b kidney transplant trial